These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18374118)

  • 1. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation?
    Kandaswamy R; Dunn T; Humar A; Sutherland DE
    Transplant Proc; 2008 Mar; 40(2):516-7. PubMed ID: 18374118
    [No Abstract]   [Full Text] [Related]  

  • 2. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation.
    Gautam A; Morrissey PE; Gohh R; Yango A; Monaco AP
    Transplant Proc; 2005 Oct; 37(8):3542-3. PubMed ID: 16298654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppression in pancreas transplantation: mycophenolate mofetil versus sirolimus.
    Garcia VD; Keitel E; Santos AF; Bianco PD; Bittar AE; Bruno RM; Garcia CD; Vitola SP; Guerra EE; Didone E; Pires F; D'Avila AJ; Goldani JJ; Bianchini JJ
    Transplant Proc; 2004 May; 36(4):975-7. PubMed ID: 15194338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors.
    Lisik W; Kahan BD
    Transplant Proc; 2006; 38(1):69-73. PubMed ID: 16504667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in immunosuppression after pancreas transplantation: what is in the pipeline?
    Kimelman M; Brandacher G
    Curr Opin Organ Transplant; 2013 Feb; 18(1):76-82. PubMed ID: 23254700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimization protocols in pancreas transplantation.
    Cantarovich D; Vistoli F
    Transpl Int; 2009 Jan; 22(1):61-8. PubMed ID: 18713147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evidences in immunosuppression in the maintenance of renal transplantation].
    Hernández D; González-Posada JM
    Nefrologia; 2005; 25(4):369-80. PubMed ID: 16231502
    [No Abstract]   [Full Text] [Related]  

  • 11. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
    Vincenti F
    Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
    [No Abstract]   [Full Text] [Related]  

  • 12. Conversion to sirolimus.
    Ruiz JC; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Grinyo JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J
    Nefrologia; 2006; 26 Suppl 2():52-63. PubMed ID: 17937634
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal immunosuppression in pancreas transplantation.
    Stratta RJ
    Transplant Proc; 1999; 31(1-2):619-21. PubMed ID: 10083263
    [No Abstract]   [Full Text] [Related]  

  • 15. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience.
    Wiseman AC; Kam I; Christians U; Jani A; Bak T; Wachs M; Chan L
    Transplant Proc; 2003 May; 35(3 Suppl):122S-124S. PubMed ID: 12742482
    [No Abstract]   [Full Text] [Related]  

  • 16. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression.
    Jordan ML; Chakrabarti P; Luke PP; Shapiro R; Vivas CA; Scantlebury VP; Hakala TR; Fedorek S; Corry RJ
    Transplant Proc; 2001; 33(1-2):1655. PubMed ID: 11267456
    [No Abstract]   [Full Text] [Related]  

  • 17. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
    Rajab A; Pelletier RP; Ferguson RM; Elkhammas EA; Bumgardner GL; Henry ML
    Transplantation; 2007 Nov; 84(9):1131-7. PubMed ID: 17998868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent results with calcineurin inhibitor-free initial immunosuppression in old recipients of old kidneys.
    Bösmüller C; Ollinger R; Mark W; Brandacher G; Schneeberger S; Cakar F; Bonatti H; Margreiter R
    Transplant Proc; 2005 Mar; 37(2):881-3. PubMed ID: 15848563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.
    Flechner SM
    Transplantation; 2009 Apr; 87(8 Suppl):S1-6. PubMed ID: 19384179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.